Outset Medical, headquartered in San Jose, California, is a private company focused on delivering much-needed technology innovation to the $13B global dialysis market. The company has developed the first dialysis machine designed as a consumer product that purifies its own water and generates dialysate on demand. Its simplicity enables patients to manage treatments independently whether in clinic or at home. With the dialysis patient population growing and dialysis reimbursement declining, Outset’s Tablo Hemodialysis System is aimed specifically at lowering costs for dialysis providers and meaningfully improving the care experience for patients. Tablo is FDA-cleared for use in dialysis clinics and hospitals, with an early market release in dialysis clinics planned for this year. The company is also pursuing FDA clearance for home use with a pivotal trial approved by the FDA and scheduled for enrollment in 2015.
Warburg Pincus led an investment in Outset in 2010 and has continued to provide additional growth capital and ongoing strategic support.